Nektar Therapeutics (NKTR), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for rezpegaldesleukin for the treatment of severe-to-very severe alopecia areata, a chronic, systemic, immune-mediated inflammatory disease.
Notably, findings from several clinical trials have demonstrated that rezpegaldesleukin safely and dose-dependently increased regulatory T cells.
The company is on track to announce topline data in December from its ongoing REZOLVE-AA Phase 2b study, involving patients with severe-to-very severe alopecia areata.
Moreover, the biotechnology company expects to collaborate with the FDA on a potential registrational program following the completion of Phase 2.
Currently, NKTR is trading at $23.55, down 0.42 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.